NEW YORK, May 13-Agencourt Bioscience will provide SNP genotyping services and develop pharmacogenomic markers for the Duke University Medical Center Department of Anesthesiology, the company said today.
The research program will probe the causes of post-surgical organ dysfunction. Agencourt will use its Sequenom mass spectrometry genotyping platform and its own genomic services capabilities to identify potential new therapeutic targets.
Agencourt and Duke did not divulge rights or financial details, and did not say how many samples would be processed through this arrangement.
"More and more of these [genotyping] studies are coming about," said Agencourt vice president and chief scientific officer Kevin McKernan. "More hospitals are having these studies lined up than biotech."